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Abstract 
Activation of the classical complement pathway represents an effector mechanism 
of intestinal ischemia/reperfusion injury.   Mice deficient in complement receptors 1 and 
2 fail to produce a component of the natural antibody repertoire that binds to ischemia-
conditioned tissues and activate complement. In contrast, mice prone to autoimmunity 
display accelerated and enhanced tissue injury that results from the binding of 
autoantibodies to injured tissues.  Our experiments demonstrate that naturally occurring 
antibodies and autoantibodies mediate tissue injury only after an organ has been 
subjected to a stressor such as ischemia.  
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1. Introduction 
Tissue injury due to ischemia and subsequent reperfusion events is a common pathology 
that occurs in multiple clinical conditions.  Organ ischemia induces immediate cellular 
injury that is significantly magnified by the return of blood flow and can lead to a 
systemic inflammatory response that damages remote organs as well. Due to the 
sensitivity of the mucosal surfaces, ischemia/reperfusion (I/R)-induced injury is 
exceptionally prominent in the intestine and frequently is followed by liver and lung 
[damage. 
Mesenteric I/R- induced mucosal tissue injury is mediated by at least two 
components, neutrophil infiltration and complement activation.  Initial studies showed 
protection from I/R-induced injury after neutrophil depletion [Hernandez, 1987 #107; 
Simpson, 1993 #127].  The involvement of complement activation in the mucosal 
damage was shown by the lack of damage in complement deficient mice (C3 or C4-/-) or 
Take-Home messages: 
• Complement inhibitors attenuate mesenteric ischemia/reperfusion induced 
tissue damage. 
•  Classical complement pathway activation mediates a significant portion of 
mesenteric ischemia/reperfusion-induced tissue damage. 
• Natural antibody repertoire contains antibodies that recognize ischemia-
conditioned tissues, activate complement and cause tissue damage. 
• Autoantibodies that recognize negatively charged phospholipids, DNA and 
histones bind to ischemia-conditioned tissues, activate complement and confer 
tissue damage. 
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after treatment with cobra venom factor that depletes C3 (1).  Treatment with soluble 
Crry-Ig allowed neutrophil infiltration without significant tissue damage indicating that 
the presence of neutrophils is not sufficient for tissue damage (2).  These studies also 
showed complement activation is critical to the induction of local mucosal damage and 
resulted in decreased systemic neutrophil activation as well (2).  Inflammatory mediators 
of the complement pathway, such as the anaphylotoxin C5a, are known to be required for 
damage to remote organs including the lungs in response to mesenteric IR (3, 4).   
 
2. Complement in Tissue Injury 
 The exact mechanism of complement activation during intestinal IR 
remains unclear as there is evidence that more than one complement pathway (classical, 
alternative or lectin) may become activated and enhance tissue injury (1, 5, 6).  However, 
two observations have strongly implicated the classical pathway in this process.  The first 
is that intestinal IR injury is significantly decreased in RAG-1-/- mice, and reconstitution 
of these Ig deficient mice with purified IgM natural antibody to normal levels restores IR-
induced injury (1).   The second is that mice with normal levels of natural antibody, but 
in which the gene encoding complement C4 is inactivated (C4-/-), are protected from 
injury (1).  From these and other findings, it has been proposed that natural antibodies 
bind to neo-antigen(s) revealed on the surface membrane of cells subjected to ischemia 
and subsequently activate complement by recruiting C1 and then cleaving C4 (1).  This is 
followed by the generation of complement C3 and C5 activation fragments with ensuing 
increases in adhesion molecule expression and release of a cascade of inflammatory 
mediators, including leukotriene B4 and others (2, 6, 7). 
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 The complement system may be important not only in the effector phases 
of tissue injury, as discussed above, but also in the development of a pathogenic subset of 
natural antibodies that recognize neo-antigens on ischemic tissue and then initiate 
intestinal IR injury.  Complement receptor type 2 (CR2/CD21) is an important membrane 
receptor that greatly enhances B cell receptor (BCR) mediated activation by binding 
complement iC3b/C3d-decorated antigens and engaging the BCR/CR2/CD19/CD81 
signaling complex (8).  This recognition mechanism lowers the threshold for activation of 
B cells (9).  In mice, CR2 is encoded along with the larger complement receptor type 1 
(CR1) by the Cr2 gene, which produces both proteins through alternative splicing of a 
common mRNA (10, 11).  CR2-/- mice demonstrate a substantial defect in the generation 
of IgG switched isotype responses (12, 13) as well as impaired B cell memory following 
immunization with T-dependent antigens (13, 14).  To determine if CR2 plays a role in 
mesenteric IR, Cr2-/- mice were subjected to intestinal IR injury and were shown to be 
protected from the induction of tissue injury (6).  Because the levels of complement 
molecules and complement activation are normal in Cr2-/- mice, other factors were 
considered to be responsible for this protection.  
The defect was shown to lie in an altered repertoire of natural antibodies because  
infusion of IgM and IgG purified from the serum of wild type C57BL/6 mice in to Cr2-/- 
mice prior to the ischemic phase resulted in reconstitution of the IR-induced injury (6).  
Of interest, transferred IgM and IgG each contributed to different aspects of tissue injury 
but together allowed the development of a complete injury phenotype (6).  These findings 
demonstrated a previously unrecognized role for complement receptors in the 
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development within the natural antibody repertoire of a tissue injury-inducing subset of 
antibodies.   
3. Autoantibodies in Tissue Injury 
 
The specific antibodies involved in I/R injury and the composition of the target 
antigen, to which recognition is lacking in Cr2-/- mice, are unknown.  Since anti-
phospholipid antibodies have been shown to mediate fetal growth retardation and loss 
when injected in to pregnant mice (15, 16), experiments were performed to determine 
whether anti-phospholipid antibodies can also reconstitute I/R injury and represent 
members of the injury-inducing repertoire that is missing in Cr2-/- mice.  Both murine 
and human monoclonal and polyclonal antibodies against negatively-charged 
phospholipids can reconstitute mesenteric I/R-induced intestinal and lung tissue damage 
in Cr2-/- mice (17).  As indicated in Table 1, antibodies against β2 glycoprotein I also 
restore local and remote tissue damage in the Cr2-/- mice. Unlike Cr2-/-  mice, 
reconstitution of I/R tissue damage in the IR injury-resistant Rag-1-/- mouse required the 
infusion of both anti- β2 glycoprotein I and anti-phospholipid antibody ((17) and Table 
1).  Therefore, anti-phospholipid antibodies can bind to tissues subjected to I/R insult and 
mediate tissue damage. 
Autoantibodies have affinity and self-antigen recognition pattern similar to 
natural antibodies.  Therefore, it is likely that autoimmunity prone mice expressing high 
titers of autoantibodies should have enhanced I/R-induced injury.  The MRL/lpr mouse 
develops clinical and serologic features similar to human systemic lupus erythematosus.    
The production of autoantibodies with multiple specificities including ssDNA, dsDNA, 
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Sm, chromatin, RNA protein complexes and phospholipids typifies the disease (18).   The 
C57BL/6-lpr/lpr  (B6.MRL/lpr) mouse shows lymphadenopathy and autoimmunity 
although the levels of certain autoantibodies are lower than those in the MRLlpr/lpr 
mouse (19, 20). It was hypothesized that autoantibodies present in the sera of mice with 
systemic autoimmunity should initiate I/R-induced organ injury in a fashion similar to 
natural antibodies.  This hypothesis predicted that autoimmunity-prone mice should 
display enhanced and accelerated I/R-induced intestinal damage and that infusion of 
autoimmune sera into I/R-resistant Rag-1-/- mice should restore organ damage.  Indeed, 
five-month-old B6.MRL/lpr mice displayed accelerated and enhanced intestinal I/R-
induced damage compared to two-month-old B6.MRL/lpr and age-matched C57Bl/6 
mice (21). Similarly, older autoimmune mice had accelerated remote organ (lung) 
damage.    Infusion of serum IgG derived from five-month but not two-month-old 
B6.MRL/lpr into I/R resistant Rag-1-/- mice rendered them susceptible to local and 
remote IR-induced organ injury (21).  Injection of monoclonal IgG anti-DNA and anti-
histone antibodies in to Rag-1-/- mice effectively reconstituted tissue injury (21).   These 
data show that like natural antibodies, autoantibodies, such as anti-dsDNA and anti-
histone antibodies, can instigate I/R injury and suggest that they are involved in the 
development of tissue damage in patients with systemic lupus erythematosus.  
The fact that natural antibodies and various autoantibodies mediate the intestinal 
ischemia reperfusion injury should not be generalized to other target organ injuries. The 
kidneys of RAG-/- mice are not resistant to IR injury implying that neither 
immunoglobulin nor mature T cells are relevant in this injury (22).     At this point more 
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information is needed on various target organ models of tissue injury to acquire a 
complete picture of the involved mechanisms.  
Based on the above information we propose that stress or injury alters the lipid 
membrane of cells such that certain antibodies found in the natural antibody repertoire 
and autoantibodies bind the cell surface and activate the complement cascade (Fig. 1). 
The ensuing complement activation leads two a two-pronged response by inducing direct 
cell lysis via membrane attack complex formation and inflammatory cell recruitment via 
the anaphylotoxins. Additional local and remote organ damage occurs as a result of 
complement activation. The production of antibodies that bind to ischemia-conditioned 
tissues require the presence of CR2 on the surface of B cells enabling the binding of 
antigen-C3dg complexes and the crosslinking the B cell receptor and CR2.  
 
The opinions contained herein are the private ones of the authors and are not to be 
constructed as official policy or reflecting the views of the Department of Defense.  
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Figure legend 
Figure 1. Proposed model of antibody mediated tissue injury. Natural antibodies able 
to recognize ischemia or stress altered cells are produced by B cells in response to 
antigen-C3dg complexes crosslinking the B cell receptor and CR2 (1). 
Autoantibodies with specificities against phospholipids, dsDNA and histones alos 
bind stressed cells (2). Complement activation induces a bi-directional response 
by inducing direct cell lysis via membrane attack complex formation and 
inflammatory cell recruitment via the anaphylotoxins (3). Additional damage 
occurs as a result of complement activation.  
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Table1: Antibodies injected prior to IR treatment. 
Antibody 
Clone  
Specificity Isotype Damage in 
Cr2-/- 
Damage in  
Rag-1-/- 
FA3 Phospholipids IgG3 Yes No 
FB1 Phospholipids IgG2b No No 
FC1 β2 GPI IgG1 Yes No 
FC2 β2 GPI IgG1 No No 
PL9-7 Histone IgG3 Yes Yes  
PL9-11 DNA IgG3 Yes Yes  
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